BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 28365833)

  • 1. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.
    Truin W; Roumen RMH; Siesling S; van de Vijver KK; Tjan-Heijnen VCG; Voogd AC
    Breast Cancer Res Treat; 2017 Jul; 164(1):133-138. PubMed ID: 28365833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast.
    Zengel B; Yararbas U; Duran A; Uslu A; Elıyatkın N; Demırkıran MA; Cengiz F; Şimşek C; Postacı H; Vardar E; Durusoy R
    Breast Cancer; 2015 Jul; 22(4):374-81. PubMed ID: 23925582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
    Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
    Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy.
    Wong H; Lau S; Cheung P; Wong TT; Parker A; Yau T; Epstein RJ
    BMC Cancer; 2014 Nov; 14():826. PubMed ID: 25385074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival analysis in patients with invasive lobular cancer and invasive ductal cancer according to hormone receptor expression status in the Korean population.
    Kwon D; Ko BK; Jung SP; Kim HK; Kim EK; Jung YS; Youn HJ; Lee SB
    PLoS One; 2022; 17(1):e0262709. PubMed ID: 35051228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
    Zhao H
    Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of DDR1 and DVL1 in invasive ductal and lobular breast carcinoma does not correlate with histological type, grade and hormone receptor status.
    Ameli F; Rose IM; Masir N
    Asian Pac J Cancer Prev; 2015; 16(6):2385-90. PubMed ID: 25824769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
    Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
    Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
    Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
    Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
    Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia.
    Petrović N; Mandušić V; Dimitrijević B; Roganović J; Lukić S; Todorović L; Stanojević B
    Med Oncol; 2014 Jun; 31(6):977. PubMed ID: 24781337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma.
    Chen Z; Yang J; Li S; Lv M; Shen Y; Wang B; Li P; Yi M; Zhao X; Zhang L; Wang L; Yang J
    PLoS One; 2017; 12(9):e0182397. PubMed ID: 28863134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.
    Narbe U; Sjöström M; Forsare C; Bendahl PO; Alkner S; Leeb-Lundberg LMF; Lövgren K; Rydén L; Ingvar C; Fernö M
    Breast Cancer Res Treat; 2019 Jun; 175(2):305-316. PubMed ID: 30796653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor characteristics and patient outcomes are similar between invasive lobular and mixed invasive ductal/lobular breast cancers but differ from pure invasive ductal breast cancers.
    Bharat A; Gao F; Margenthaler JA
    Am J Surg; 2009 Oct; 198(4):516-9. PubMed ID: 19800459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade.
    Metzger-Filho O; Ferreira AR; Jeselsohn R; Barry WT; Dillon DA; Brock JE; Vaz-Luis I; Hughes ME; Winer EP; Lin NU
    Oncologist; 2019 Jul; 24(7):e441-e449. PubMed ID: 30518616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma.
    Jung NY; Kim SH; Choi BB; Kim SH; Sung MS
    World J Surg Oncol; 2015 Mar; 13():113. PubMed ID: 25889560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Infiltration in Invasive Lobular Breast Cancer.
    Desmedt C; Salgado R; Fornili M; Pruneri G; Van den Eynden G; Zoppoli G; Rothé F; Buisseret L; Garaud S; Willard-Gallo K; Brown D; Bareche Y; Rouas G; Galant C; Bertucci F; Loi S; Viale G; Di Leo A; Green AR; Ellis IO; Rakha EA; Larsimont D; Biganzoli E; Sotiriou C
    J Natl Cancer Inst; 2018 Jul; 110(7):768-776. PubMed ID: 29471435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology.
    Moran MS; Yang Q; Haffty BG
    Breast J; 2009; 15(6):571-8. PubMed ID: 19995377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed invasive ductal and lobular carcinoma has distinct clinical features and predicts worse prognosis when stratified by estrogen receptor status.
    Xiao Y; Ma D; Ruan M; Zhao S; Liu XY; Jiang YZ; Shao ZM
    Sci Rep; 2017 Sep; 7(1):10380. PubMed ID: 28871133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights.
    Da Ros L; Moretti A; Querzoli P; Pedriali M; Lupini L; Bassi C; Carcoforo P; Negrini M; Frassoldati A
    Clin Breast Cancer; 2018 Oct; 18(5):e1133-e1139. PubMed ID: 29759595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.